×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Multi-stakeholder considerations for sustainable clinical trials – why is it important and what action is needed?
Session Chair(s)
Daniel Reed, PhD
Senior Regulatory Intelligence Director
AstraZeneca, United Kingdom
Claudia Percivalle, PhD, MSc
Regulatory Affairs Director
AstraZeneca, United Kingdom
Multi-stakeholder considerations for sustainable clinical trials – why is it important and what action is needed?
Have an account?